

# Alessandro Del Conte

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8025212/publications.pdf>

Version: 2024-02-01

48  
papers

1,412  
citations

516215

16  
h-index

329751

37  
g-index

48  
all docs

48  
docs citations

48  
times ranked

2620  
citing authors

#	ARTICLE	IF	CITATIONS
1	First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. <i>Oncologist</i> , 2022, 27, 87-e115.	1.9	25
2	Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6936.	1.8	8
3	Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1368-1376.	0.4	13
4	Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. <i>Future Oncology</i> , 2021, 17, 2513-2527.	1.1	7
5	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. <i>Clinical Lung Cancer</i> , 2020, 21, 1-14.e3.	1.1	19
6	Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study. <i>Clinical and Translational Oncology</i> , 2020, 22, 294-301.	1.2	4
7	Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. <i>Lung Cancer</i> , 2020, 140, 71-79.	0.9	8
8	A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Diagnostics</i> , 2020, 10, 765.	1.3	7
9	Diagnostic Accuracy of Pleural Fluid Cytology, Carcinoembryonic Antigen and C-Reactive Protein Together in Patients With Pulmonary Metastases and Malignant Pleural Effusion. <i>Anticancer Research</i> , 2020, 40, 5877-5881.	0.5	6
10	First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. <i>European Journal of Cancer</i> , 2020, 130, 155-167.	1.3	98
11	Diagnosis of Malignant Pleural Effusion Using CT Scan and Pleural-Fluid Cytology Together. A Preliminary Case-Control Study. <i>Anticancer Research</i> , 2020, 40, 1135-1139.	0.5	8
12	Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience. <i>Cytokine</i> , 2019, 113, 50-60.	1.4	5
13	Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. <i>Lung Cancer</i> , 2019, 134, 210-217.	0.9	12
14	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669.	5.1	418
15	Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report. <i>In Vivo</i> , 2019, 33, 2021-2026.	0.6	3
16	Esophageal ultrasound with ultrasound bronchoscope (EUS-B) guided left adrenal biopsy: Case report with review of literature. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 154-156.	0.2	1
17	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , 2019, 132, 17-23.	0.9	12
18	Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20612-e20612.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Cyclophosphamide, Fluorouracil and subcutaneous Interleukin-2 in the treatment of advanced GIST: A Case Report. <i>Surgical Case Reports</i> , 2019, , 1-5.	0.0	0
20	Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey. <i>Supportive Care in Cancer</i> , 2018, 26, 1841-1849.	1.0	10
21	Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. <i>Radiotherapy and Oncology</i> , 2018, 126, 177-180.	0.3	116
22	Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. <i>European Journal of Cancer</i> , 2018, 100, 126-134.	1.3	83
23	Listening understanding and acting (lung): focus on communicational issue in thoracic oncology. <i>Translational Cancer Research</i> , 2018, 8, S16-S22.	0.4	0
24	A randomized phase II trial of maintenance oral metronomic vinorelbine versus close observation in advanced non-small cell lung cancer (NSCLC) following platinum-based chemotherapy: MA.NI.LA. trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21101-e21101.	0.8	0
25	Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non-small-cell Lung Cancer: A Multicenter Italian Survey. <i>Clinical Lung Cancer</i> , 2017, 18, 381-387.	1.1	6
26	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. <i>Clinical Cancer Research</i> , 2017, 23, 3316-3324.	3.2	43
27	Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1476.	2.2	54
28	Cyclophosphamide with (+)/without (-) fluorouracil followed by subcutaneous or intravenous interleukin-2 in solid tumors: An off-label experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14621-e14621.	0.8	1
29	Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC. <i>Anticancer Research</i> , 2017, 37, 3189-3194.	0.5	20
30	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 31-37.	0.9	31
31	51P Diagnostic value of carcinoembryonic antigen, lactate dehydrogenase and C-reactive protein in patients with pleural effusion undergoing VATS thoracentesis. <i>Journal of Thoracic Oncology</i> , 2016, 11, S76.	0.5	0
32	77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC). <i>Journal of Thoracic Oncology</i> , 2016, 11, S88.	0.5	1
33	49P Accuracy of pleural fluid cytology in patients with malignant pleural effusion from non-small-cell lung cancer, pulmonary metastases and pleural mesothelioma. A case-control study. <i>Journal of Thoracic Oncology</i> , 2016, 11, S75.	0.5	0
34	Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. <i>Future Oncology</i> , 2016, 12, 373-387.	1.1	43
35	Randomized, double-blind, placebo-controlled trial of evofosfamide (Evo) and pemetrexed (Pem) in advanced non-squamous non-small cell lung cancer (n-s NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9075-9075.	0.8	0
36	Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 606-613.	0.4	42

#	ARTICLE	IF	CITATIONS
37	Everolimus plus exemestane for hormone resistant metastatic breast cancer (MBC): A single institutional experience.. Journal of Clinical Oncology, 2015, 33, e11576-e11576.	0.8	0
38	Stereotactic Body Radiation Therapy for Re-irradiation of Persistent or Recurrent Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1114-1119.	0.4	79
39	Neoadjuvant chemotherapy with nonpegylated liposome-encapsulated doxorubicin (NPLD) plus cyclophosphamide followed by trastuzumab plus nabpaclitaxel for HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2014, 32, 648-648.	0.8	1
40	Offlabel nab-paclitaxel: Gemcitabine chemotherapy in advanced pancreatic cancerâ€”A monoinstitutional experience.. Journal of Clinical Oncology, 2014, 32, e15239-e15239.	0.8	0
41	Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification. Breast, 2013, 22, 1101-1107.	0.9	16
42	Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen. BMC Cancer, 2013, 13, 513.	1.1	16
43	Tomotherapy after Pleurectomy/Decortication or Biopsy for Malignant Pleural Mesothelioma Allows the Delivery of High Dose of Radiation in Patients with Intact Lung. Journal of Thoracic Oncology, 2012, 7, 1862-1866.	0.5	53
44	Interleukin-2 (IL-2) chrono-infusion (CHI) in metastatic renal cell carcinoma (mRCC): A phase I/II study.. Journal of Clinical Oncology, 2012, 30, 423-423.	0.8	0
45	Expression pattern of receptor activator of NF $\kappa$ B (RANK) in a series of primary solid tumors and related bone metastases. Journal of Cellular Physiology, 2011, 226, 780-784.	2.0	118
46	Bisphosphonate-Induced Osteonecrosis of the Jaw 32 Months After Interruption of Zoledronate in a Patient With Multiple Myeloma. Journal of Oral and Maxillofacial Surgery, 2010, 68, 1179-1182.	0.5	9
47	Fludarabine combination therapy for follicular lymphoma followed by acute myeloid leukemia: two further case records. Leukemia, 2008, 22, 1781-1782.	3.3	1
48	Complete Response of Colorectal Liver Metastases after Intra-Arterial Chemotherapy. Tumori, 2008, 94, 489-492.	0.6	15